01
Dec
AstraZeneca has made significant strides in lung cancer treatment, showcasing promising results for its drugs Tagrisso and Imfinzi at the American Society of Clinical Oncology (ASCO) annual meeting. These advancements are set to change the standard of care for many patients with advanced lung cancer. Key Takeaways Tagrisso significantly reduces cancer progression in stage 3 lung cancer patients with EGFR mutations. Imfinzi shows improved survival rates in patients with limited-stage small cell lung cancer. Datopotamab deruxtecan demonstrates potential despite not meeting all endpoints in a Phase 3 study. Tagrisso's Impact on Stage 3 Lung Cancer AstraZeneca's Tagrisso has shown remarkable…
